Tumor Microbiome Analysis for Immunotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in predicting responsiveness to therapy due to the complex interaction between tumor cells and their microenvironment, particularly the role of intra-tumor bacteria, which has not been comprehensively characterized.
Innovation Solution
Analyzing the abundance of specific bacteria in the tumor microbiome to determine the suitability of immunotherapy treatment and delivering therapeutic or diagnostic agents using bacteria linked to these microbiome components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive characterization of intra-tumor bacteria is performed, then prediction accuracy of therapy responsiveness is improved, but device complexity and analysis cost increase
Solution Approach 1:
The patent segments the complex task of comprehensive bacterial characterization into analysis of specific bacterial taxa at different taxonomic levels (phylum, class, order, family, genus, species). This allows focused analysis on clinically relevant bacteria rather than attempting to characterize all bacteria simultaneously, thereby improving prediction accuracy while managing analysis complexity.
Solution Approach 2:
The patent develops a universal bacterial signature framework that can be applied across multiple cancer types (melanoma, lung cancer, colorectal cancer, etc.) and multiple immunotherapy treatments (checkpoint inhibitors, cancer vaccines, adoptive cell therapy). This multi-functional approach improves prediction accuracy across diverse clinical scenarios while avoiding the need to develop separate complex analysis systems for each cancer type or treatment.
2Reliability
If tumor microbiome analysis is performed to identify responsive candidates, then treatment effectiveness is improved, but loss of time in diagnosis and treatment selection increases
Solution Approach 1:
The patent performs preliminary analysis of the tumor microbiome composition before initiating immunotherapy treatment. By characterizing the bacterial signature in advance (using 16S rRNA gene sequencing or metagenomic approaches), the system identifies patients likely to respond to immunotherapy beforehand, allowing for optimized treatment selection without delaying overall treatment initiation.
Solution Approach 2:
The patent replaces traditional trial-and-error or clinically-intensive diagnostic methods with molecular-based microbiome analysis. By using DNA sequencing technologies to directly characterize bacterial communities in tumor samples, the system achieves rapid, high-throughput analysis that reduces diagnosis time compared to conventional methods while maintaining high reliability in predicting treatment responsiveness.
3Manufacturing precision
If bacteria are used to deliver therapeutic agents to tumors, then manufacturing precision of targeted delivery is improved, but object-generated harmful factors may increase
Solution Approach 1:
The patent uses bacteria as intermediary carriers to deliver therapeutic agents specifically to the tumor microenvironment. The bacteria naturally accumulate in tumors through the enhanced permeability and retention (EPR) effect and by exploiting tumor-associated inflammation, thereby achieving precise targeted delivery. This intermediary approach allows the therapeutic payload to be delivered directly to the tumor site while minimizing exposure to healthy tissues, reducing potential side effects.
Data Source
AI summary
A method of treating cancer in a subject is disclosed. The method comprises:(a) analyzing for the abundance of at least one bacteria in the tumor microbiome of the subject; and(b) administering to the subject a therapeutically effective amount of an immunotherapy treatment on the basis of the abundance of said at least one bacteria.